升陷汤通过Hippo通路增强调节性T细胞免疫抑制活性改善实验性自身免疫性重症肌无力
本研究以泼尼松为阳性对照,在重组乙酰胆碱受体α亚基97-116肽诱导的实验性自身免疫性重症肌无力(EAMG)大鼠模型中探究升陷汤的疗效及机制。结果显示升陷汤可逆转体重和肌力下降、减轻炎症并修复胸腺损伤,其机制可能与通过TAZ/TEAD通路促进TAZ降解、抑制TAZ与TEAD结合,从而恢复Treg/Th1/Th17平衡有关。
要点
- 升陷汤可改善EAMG大鼠体重下降和肌力减退,减轻炎症并修复胸腺组织损伤。
- 升陷汤上调FOXP3和TEAD、下调TAZ,抑制TAZ与TEAD结合,增强Treg免疫抑制活性。
- 升陷汤可能通过TAZ/TEAD通路恢复Treg与Th1/Th17平衡,发挥治疗EAMG作用。
核心结论
- 升陷汤具有治疗实验性自身免疫性重症肌无力的作用,其机制可能通过TAZ/TEAD通路促进TAZ降解并抑制TAZ与TEAD结合,恢复机体免疫功能平衡。
研究设计与样本
- 采用泼尼松作为阳性对照,使用重组乙酰胆碱受体α亚基97-116肽诱导的EAMG大鼠模型评估升陷汤疗效。
- 通过动物行为学结合重复神经刺激实验进行模型评价,采用HE染色和ELISA检测炎症因子水平,流式细胞术观察T细胞免疫变化。
- 采用免疫组化和免疫荧光检测TAZ、TEAD和FOXP3分子表达,并通过Western blot和免疫共沉淀在体内外验证机制。
主要发现
- 升陷汤显著逆转EAMG大鼠体重和肌力下降,降低炎症水平并修复胸腺组织损伤。
- 升陷汤显著增加促炎性Th1和Th17细胞比例并降低调节性T细胞(Treg)表达,改变EAMG大鼠的免疫失衡趋势。
- 升陷汤上调FOXP3和TEAD表达、下调TAZ表达,并抑制TAZ与TEAD的结合,该现象在体外实验中得到验证。
临床怎么用
- 升陷汤作为经典中药方剂,在EAMG模型中显示出改善肌力和免疫调节的潜力,可能为重症肌无力治疗提供候选方案。
- 其作用机制涉及TAZ/TEAD通路调控Treg/Th1/Th17平衡,提示该通路可作为重症肌无力中药干预的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies, the pathogenesis of which is well defined but for which safe and effective drugs are still lacking. Shengxian Decoction (SXD) is a classical Chinese herbal formula that has been shown to improve qi deficiency and fatigue syndrome, which is also one of the key pathomechanisms in myasthenia gravis. However, the potential of this formula to treat myasthenia gravis (MG) and its underlying mechanisms remains to be fully elucidated. AIM OF THE STUDY: To investigate the therapeutic effect of the traditional Chinese medicine formula, Shengxian Decoction (SXD) on MG and its potential mechanism of action. METHODS AND MATERIALS: Employing prednisone (PDN) as a positive control, the experimental autoimmune myasthenia gravis (EAMG) rat model induced by recombinant acetylcholine receptor (AChR) α subunit 97-116 peptide was used to reveal and confirm the therapeutic effect of SXD on MG. Model evaluation was performed based on animal behavioral performance combined with repeated nerve stimulation (RNS) experiments. Hematoxylin-Eosin (HE) staining and enzyme-linked immunosorbent (ELISA) assay were used to detect the level of inflammatory cytokines. The alterations in T-cell immunity were observed using flow cytometry (FCM). Immunohistochemistry (IHC) and immunofluorescence (IF) experiments were used to detect the molecular expression of TAZ, TEAD, and FOXP3. The ex vivo and in vivo mechanisms were validated by Western blot (WB) and Co-immunoprecipitation (Co-IP). RESULTS: The results showed that SXD significantly reversed loss of weight and muscle strength in EAMG rats, reducing the inflammation level and repairing the damage of thymic tissues in the model rats. Furthermore, SXD altered the trend observed in EAMG rats by markedly increasing the proportion of pro-inflammatory Th1 and Th17 cells and reducing the expression of Regulatory T cells (Treg), which plays a pivotal role in regulating the immune response in EAMG rats. SXD was shown to upregulate the expression of FOXP3 and TEAD, downregulate the expression of TAZ, and inhibit the binding of TAZ and TEAD in this research. This phenomenon was subsequently validated in vitro, which may elucidate the potential mechanism of SXD in the treatment of EAMG. CONCLUSION: SXD has been demonstrated to possess the capacity to treat EAMG. The underlying mechanism of action may be achieved by promoting the degradation of TAZ through the TAZ/TEAD pathway and inhibiting the binding of TAZ and TEAD, thereby restoring the balance of the body's immune function.
引用
- Wang S, Zhang X, Bai Y, et al. Shengxian decoction alleviates experimental autoimmune myasthenia gravis by enhancing the immunosuppressive activity of regulatory T cells via Hippo pathway. J Ethnopharmacol. 2025. PMID: 40619040. doi:10.1016/j.jep.2025.120250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。